Application of MALDI-TOF mass spectrometry in screening and diagnostic research

Current Pharmaceutical Design

Volumn 11, Issue 20, 2005, Pages 2577-2591

  Pusch, W ^a,b   Kostrzewa, M ^a,b  

^a BRUKER DALTONIK GMBH   (Germany)

^b NONE   (Germany)

Author keywords

Biomarkers; Diagnosis; MALDI TOF; Quality control; Screening; Serum profiling; SNP genotyping

Indexed keywords

DNA; OLIGONUCLEOTIDE; PEPTIDE; PROTEIN;

AUTOMATION; BIOCHEMISTRY; CALCULATION; CANCER; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; NUCLEIC ACID ANALYSIS; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; QUALITY CONTROL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOMEDICAL RESEARCH; CLINICAL LABORATORY TECHNIQUES; HUMANS; MASS SCREENING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 22944438393     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612054546932     Document Type: Review

References (78)

1. Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Analytical Chemistry 1988; 60(20): 2299-2301.
2. Hillenkamp F, Karas M. Mass spectrometry of peptides and proteins by matrix-assisted ultraviolet laser desorption/ionization. Methods Enzymol 1990; 193: 280-295.
3. Hillenkamp F, Karas M, Beavis RC, Chait BT. Matrix-assisted laser desorption/ionization mass spectrometry of bioploymers. Analytical Chemistry 1991; 63(24): 1193A-1203A.
4. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989; 246(4926): 64-71.
5. Lechner D, Lathrop GM, Gut IG. Large-scale genotyping by mass spectrometry: experience, advances and obstacles. Curr Opin Chem Biol 2002; 6(1): 31-8.
6. Sickmann A, Mreyen M, Meyer HE. Mass spectrometry - a key technology in proteome research. Adv Biochem Eng Biotechnol 2003; 83: 141-76.
7. Ashcroft AE. Protein and peptide identification: the role of mass spectrometry in proteomics. Nat Prod Rep 2003; 20(2): 202-15.
8. Pusch W, Wurmbach JH, Thiele H, Kostrzewa M. MALDI-TOF mass spectrometry-based SNP genotyping. Pharmacogenomics 2002; 3(4): 537-548.
9. Grant GA, Frison SL, Yeung J, Vasanthan T, Sporns P. Comparison of MALDI-TOF mass spectrometric to enzyme colorimetric quantification of glucose from enzyme-hydrolyzed starch. J Agric Food Chem 2003; 51(21): 6137-44.
10. Dell A, Morris HR. Giycoprotein structure determination by mass spectrometry. Science 2001; 291(5512): 2351-6.
11. Harvey DJ. Identification of protein-bound carbohydrates by mass spectrometry. Proteomics 2001; 1(2): 311-28.
12. Harvey DJ. Matrix-assisted laser desorption/ionization mass spectrometry of carbohydrates. Mass Spectrom Rev 1999; 18(6): 349-450.
13. Cohen LH, Gusev AI. Small molecule analysis by MALDI mass spectrometry. Anal Bioanal Chem 2002; 373(7): 571-86.
14. Guzey C, Spigset O. Genotyping of drug targets: a method to predict adverse drug reactions? Drug Saf 2002; 25(8): 553-60.
15. Izawa H, Yamada Y, Okada T, Tanaka M, Hirayama H, Yokota M. Prediction of genetic risk for hypertension. Hypertension 2003; 41(5): 1035-40.
16. Rose CM, Marsh S, Ameway MM, McLeod HL. Pharmacogenetic analysis of clinically relevant genetic polymorphisms. Methods Mol Med 2003; 85: 225-37.
17. Ye J, Parra EJ, Sosnoski DM, Hiester K, Underhill PA, Shriver MD. Melting curve SNP (McSNP) genotyping: a useful approach for diallelic genotyping in forensic science. J Forensic Sci 2002; 47(3): 593-600.
18. Linacre A, Graham D. Role of molecular diagnosticcs in forensic science. Expert Rev Mol Diagn 2002; 2(4): 346-53.
19. Leushner J, Chin NH. Automated mass spectrometry: a revolutionary technology for clinical diagnostics. Mol Diagn 2000; 5(4): 341-8.
20. Humeny A, Bonk T, Berkholz A, Wildt L, Becker CM. Genotyping of thrombotic risk factors by MALDI-TOF mass spectrometry. Clin Biochemistry 2001; 34(7): 531-6.
21. Kato N. Genetic analysis in hypertension. Hypertension Research 2002; 25(3): 319-27.
22. Ross JS, Ginsburg GS. Integration of molecular diagnostics with therapeutics: implications for drug discovery and patient care. Expert Rev Mol Diag 2002; 2(6): 531-40.
23. Little DP, Braun A, Darnhofer-Demar B, Koster H. Identification of apolipoprotein E polymorphisms using temperature cycled primer oligo base extension and mass spectrometry. Eur J Clin Chem Clin Biochem 1997; 35(7): 545-8.
24. Pusch W, Kraeuter KO, Froehlich T, Stalgies Y, Kostrzewa M. genotools "SNP manager": A new software for automated high-throughput MALDI-TOF mass spectrometry SNP genotyping. Biotechniques 2001; 30(1): 210-5.
25. Sauer S, Lechner D, Berlin K, Plancon C, Heuermann A, Lehrach H, et al. Full flexibility genotyping of single-nucleotide polymorphisms by the GOOD assay. Nucleic Acids Research 2000; 28(33): E100.
26. Griffin TJ, Hall JG, Prudent JR. Smith LM. Direct genetic analysis by matrix-assisted laser desorption/ionization mass spectrometry. Proc Natl Acad Sci USA 1999; 96(11): 6301-6.
27. Mein Ca, Barratt BJ, Dunn MG, Siegmund T, Smith AN, Esposito L, et al. Evaluation of single nucleotide polymorphism typing with invader on PCR amplicons and its automation. Genome Res 2000; 10(3): 330-43.
28. Fei Z, Smith LM. Analysis of single nucleotide polymorphisms by primer extension and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 2000;14(11): 950-9.
29. Stoerker J, Mayo JD, Tetzlaff CN, Sarracino DA, Schwope I, Richert C. Rapid genotyping by MALDI-monitored nuclease selection from probe libraries. Nature Biotechnology 2000; 18(11): 1213-1216.
30. Ross PL, Lee K, Belgrader P. Discrimination of single-nucleotide polymorphisms in human DNA using peptide nucleic acid probes detected by MALDI-TOF mass spectrometry. Anal Chem 1997; 69(20): 4197-202.
31. Krook A, Stratton IM, O'Rahilly S. Rapid and simultaneous detection of multiple mutations by pooled and multiplex single nucleotide primer extension: application to the study of insulin-responsive glucose transporter and insulin receptor mutations in non-insulin-dependent diabetes. Hum Mol Genet 1992;1(6): 391-5.
32. Ross P, Hall L, Smirnov I, Haff L. High level multiplex genotyping by MALDI-TOF mass spectrometry. Nature Biotechnology 1998; 16: 1347-1351.
33. Fei Z, Ono T, Smith LM. MALDI-TOF mass spectrometric typing of single nucleotide polymorphisms with mass-tagged ddNTPs. Nucleic Acids Res 1998; 26(11): 2827-8.
34. Sauer S, Gelfand DH, Boussicault P, Bauer K, Reichert F, Gut IG. Facile method for automated genotyping of single nucleotide polymorphisms by mass spectrometry. Nucleic Acids Res 2002; 30(5): e22.
35. Li J, Butler JM, Tan Y, Lin H, Royer S, Ohler L, et al. Single nucleotide polymorphism determination using primer extension and time-of-flight mass spectrometry. Electrophoresis 1999; 20(6): 1258-65.
36. Wenzel T, Elssner T, Fahr K, Bimmler J, Richter S, Thomas I, et al. Genosnip: SNF genotyping by MALDI-TOF MS using photocleavable oligonucleotides. Nucleosides Nucleotides Nucleic Acids 2003; 22(5-8): 1579-81.
37. Nordhoff E, Luebbert C, Thiele G, Heiser V, Lehrach H. Rapid determination of short DNA sequences by the use of MALDI-MS. Nucleic Acids Res 2000; 28(20): E86.
38. Fu DJ, Broude NE, Koster H, Smith CL, Cantor CR. Efficient preparation of short DNA sequence ladders potentially suitable for MALDI-TOF DNA sequencing. Genet Anal 1996;12(3-4): 137-42.
39. Berkenkamp S, Kirpekar F, Hillenkamp F. Infrared MALDI mass spectrometry of large nucleic acids. Science 1998; 281(5374): 260-2.
40. Rodi CP, Darnhofer-Patel B, Stanssens P, Zabeau M, van den Boom D. A strategy for the rapid discovery of disease markers using the MassARRAY system. Biotechniques 2002; Suppl 62-6: 68-9.
41. Hartmer R, Storm N, Boecker S, Rodi CP, Hillenkamp F, Jurinke C, et al. RNase T1 mediated base-specific cleavage and MALDI-TOF MS for high-throughput comparative sequence analysis. Nucleic Acids Res 2003; 3(9): e47.
42. Krebs S, Medugorac I, Seichter D, Forster M. RNaseCut: a MALDI mass spectrometry-based method for SNP discovery. Nucleic Acids Res 2003; 31(7): e37.
43. Ross P, Hall L, Haff LA. Quantitative approach to single-nucleotide polymorphism analysis using MALDI-TOF mass spectrometry. Biotechniques 2000; 29(3): 620-629.
44. Buetow KH, Edmonson M, MacDonald R, Clifford R, Yip P, Kelley J, et al. High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci USA 2001; 98(2): 581-584.
45. Tost J, Brandt O, Boussicault F, Derbala D, Caloustian C, Lechner D, et al. Molecular haplotyping at high throughput. Nucleic Acids Res 2002; 30(19): e96.
46. Tost J, Schatz P, Schuster M, Berlin K, Gut IG. Analysis and accurate quantification of CpG methylation by MALDI mass spectrometry. Nucleic Acids Res 2003; 31(9): e50.
47. Ding C, Cantor CR. A high-throughput gene expression analysis technique using competitive PCR and matrix-assisted laser desorption ionization time-of-flight MS. Proc Natl Acad Sci USA 2003; 100(6): 3059-64.
48. De Bellis G, Salani G, Battaglia C, Pietta P, Rosti E, Mauri P. Electrospray ionization mass spectrometry of synthetic oligonucleotides using 2-propanol and spermidine. Rapid Commun Mass Spectrom 2000; 14(4): 243-9.
49. Hathaway GM. Characterization of modified and normal deoxyoligonucleotides by MALDI, time-of-flight mass spectrometry. Biotechniques 1994; 17(1): 150-5.
50. Ball RW, Packman LC. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry as a rapid quality control method in oligonucleotide synthesis. Anal Biochem 1997; 246(2): 185-94.
51. Butler JM, Devaney JM, Marino MA, Vallone PM. Quality control of PCR primers used in multiplex STR amplification reactions. Forensic Sci Int 2001;119(1): 87-96.
52. Triolo A, Altamura M, Cardinali F, Sisto A, Maggi CA. Mass spectrometry and combinatorial chemistry: a short outline. J Mass Spectrom 2001; 36(12): 1249-59.
53. Shah N, Gao M, Tsutsui K, Lu A, Davis J, Scheuermann R, et al. A novel approach to high-throughput quality control of parallele synthesis libraries. J Comb Chem 2000; 2(5): 453-60.
54. Mathur S, Hassel M, Steiner F, Hollemeyer K, Hartmann RW. Development of a new approach for screening combinatorial chemistry libraries using MALDI-TOF-MS and HPLC-ESI-MS/MS. J Biomol Screen 2003; 8(2): 136-48.
55. Haring N, Salama Z, Jaeger H. Triple quadrupole mass spectrometric determination of bromocriptine in human plasma with negative ion chemical ionization. Arzneimittelforschung 1988; 38(19): 1529-32.
56. Isbell J, Xu R, Cai Z, Kassel DB. Realities of high-throughput liquid chromatography/mass spectrometry purification of large combinatorial libraries: a report on overall sample throughput using parallel purification. J Comb Chem 2002; 4(5): 600-11.
57. Leister W, Strauss K, Wisnoski D, Zhao Z, Lindsley C. Development of a custom high-throughput preparative liquid chromatography/mass spectrometry platform for the preparative purification and analytical analysis of compound libraries. J Comb Chem 2003; 5(3): 322-9.
58. Xu R, Nemes C, Jenkins KM, Rourick RA, Kassel DB, Liu CZ. Application of parallel liquid chromatography/mass spectrometry for high throughput microsomal stability screening of compound libraries. J Am Soc Mass Spectrom 2002; 13(2): 155-65.
59. Sussmuth RD, Jung G. Impact of mass spectrometry on combinatorial chemistry. J Chromatogr B Biomed Sci Appl 1999; 725(1): 49-65.
60. Pusch W, Flocco MT, Leung SM, Thiele H, Kostrzewa M. Mass spectrometry-based clinical proteomics. Pharmacogenomics 2003; 4(4): 463-476.
61. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. The Lancet 2002; 359: 572-577.
62. Sorace JM, Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 2003; 4(1): 24. Epub 2003 Jun 09.
63. Pritzker KPH. Cancer biomarkers: Easier said than done. Clinical Chemistry 2002; 4(8): 1147-1150.
64. Fung ET, Enderwick C. ProteinChip clinical proteomics: Computational challenges and solutions. Biotechniques 2002; Suppl 34-8: 40-1.
65. Adam B, Qu Y, Davis JW, Ward MD, Clements, MA, Cazares, LH, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Research 2002; 62: 3609-3614.
66. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clinical Chemistry 2002; 48(10): 1835-1843.
67. Li J, Zhang Z, Resenzweig J, Wang YY, Chan D. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clinical Chemistry 2002; 48(8): 1296-1304.
68. Cuzick J, Edwards R. Methods for investigating localized clustering of disease. Clustering methods based on k nearest neighbour distributions. IARC Sci Pabl 1996;(135): 53-67.
69. Carroll PG, DeWolf WC, Mehra CR, Rohan JE, Yunis EJ. Centroid cluster analysis of the primed lymphocyte test. Transplant Proc 1979; 11(4): 1809-12.
70. Whitaker D, Walker H. Centroid evaluation in the vernier alignment of random dot clusters. Vision Res 1988; 28(7): 777-84.
71. Kia SJ, Coghil GG. Unsupervised clustering and centroid estimation using dynamic competitive learning. Biol Cybern 1992; 67(5): 433-43.
72. Zhang Z, Chan DW. Unified Maximum Separability Analysis a supervised approach for biological expression data analysis. http://www.aacc.org/meetings/oakridge/2002/abstracts/OCRabs26.pdf.
73. Pitt MA, Myung IJ. When a good fit can be bad. Trends Cogn Sci 2002; 6(10): 421-425.
74. Cai YD, Liu XJ, Xu XB, Chou, KC. Support vector machines for the classification and prediction of beta-turn types. J Pept Sci 2002; 8(7): 297-301.
75. Hua S, Sun Z. A novel method of protein secondary structure prediction with high segment overlap measure: support vector machine approach. Journal of Molecular Biology 2001; 308(2): 397-402.
76. Aune TM, Maas K, Moore JH, Olsen NJ. Gene expression profiles in human autoimmune disease. Curr Pharm Design 2003; 9(23): 1905-17.
77. Liu S, Jiang S. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques. Curr Pharm Design 2004; 10(15): 1827-43.
78. Wolfl S, Burchert A, Kroll TC. Monitoring therapy with gene expression profiling reveals physiological differences in drug action. Curr Pharm Design 2004; 10(16): 1959-68.